Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the fluoroquinolone class and features a fused benzothiadiazine ring. It was discovered as part of a new class of hepatitis C virus (HCV) polymerase inhibitors through high-throughput screening by GlaxoSmithKline. The compound potently inhibits HCV RNA-dependent RNA polymerase activity and blocks replication in cellular models. It has demonstrated excellent potency in biochemical and cellular assays but has not advanced to clinical development or approval[5][2]. Its primary mechanism is antiviral activity targeting viral replication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-(2-cyclopropylethyl)-3-(1,1-dioxo-2H-1,2,4-benzothiadiazin-3-yl)-6-fluoro-4-hydroxy-2(1H)-quinolinone.